SI3555105T1 - Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 - Google Patents

Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2

Info

Publication number
SI3555105T1
SI3555105T1 SI201730488T SI201730488T SI3555105T1 SI 3555105 T1 SI3555105 T1 SI 3555105T1 SI 201730488 T SI201730488 T SI 201730488T SI 201730488 T SI201730488 T SI 201730488T SI 3555105 T1 SI3555105 T1 SI 3555105T1
Authority
SI
Slovenia
Prior art keywords
phenylethylamino
pyrimido
oxazin
compounds
mutant idh1
Prior art date
Application number
SI201730488T
Other languages
English (en)
Inventor
Renato Alejandro Bauer
Serge Louis Boulet
Timothy Paul Burkholder
Raymond Gilmour
Patric James Hahn
Zoran Rankovic
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI3555105T1 publication Critical patent/SI3555105T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201730488T 2016-12-16 2017-12-08 Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2 SI3555105T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16
EP17822882.1A EP3555105B1 (en) 2016-12-16 2017-12-08 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
PCT/US2017/065246 WO2018111707A1 (en) 2016-12-16 2017-12-08 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Publications (1)

Publication Number Publication Date
SI3555105T1 true SI3555105T1 (sl) 2020-12-31

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730488T SI3555105T1 (sl) 2016-12-16 2017-12-08 Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2

Country Status (36)

Country Link
US (3) US11001596B2 (sl)
EP (2) EP3763717B1 (sl)
JP (1) JP6793836B2 (sl)
KR (1) KR102276022B1 (sl)
CN (2) CN115109075A (sl)
AU (2) AU2017378060B2 (sl)
CA (1) CA3045303C (sl)
CL (1) CL2019001551A1 (sl)
CO (1) CO2019005287A2 (sl)
CR (1) CR20190252A (sl)
CY (1) CY1123577T1 (sl)
DK (1) DK3555105T3 (sl)
DO (1) DOP2019000163A (sl)
EA (1) EA036112B1 (sl)
EC (1) ECSP19042682A (sl)
ES (2) ES2941631T3 (sl)
HR (1) HRP20201882T1 (sl)
HU (1) HUE052067T2 (sl)
IL (1) IL267236B (sl)
JO (1) JOP20190142B1 (sl)
LT (1) LT3555105T (sl)
MA (2) MA53881A (sl)
MD (1) MD3555105T2 (sl)
MX (1) MX2019006830A (sl)
MY (1) MY197313A (sl)
NZ (1) NZ754115A (sl)
PE (1) PE20190977A1 (sl)
PH (1) PH12019501328A1 (sl)
PL (1) PL3555105T3 (sl)
PT (1) PT3555105T (sl)
RS (1) RS61108B1 (sl)
SA (1) SA519401897B1 (sl)
SI (1) SI3555105T1 (sl)
TN (1) TN2019000158A1 (sl)
UA (1) UA123640C2 (sl)
WO (1) WO2018111707A1 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3194383B1 (en) 2014-09-19 2019-11-06 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2016044789A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016044782A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015317327B9 (en) 2014-09-19 2020-04-09 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
CA3040040A1 (en) 2016-10-24 2018-05-03 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
PE20191105A1 (es) 2016-12-16 2019-08-23 Janssen Pharmaceutica Nv Inhibidores de moleculas pequenas de lafamilia de quinasas jak
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PE20190977A1 (es) * 2016-12-16 2019-07-09 Lilly Co Eli Compuestos de 7-feniletilamino-4h-pirimido [4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e ihd2 mutantes
LT3494116T (lt) 2017-01-30 2020-01-10 Astrazeneca Ab Estrogeno receptorių moduliatoriai
WO2019222553A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20230000871A1 (en) * 2019-11-08 2023-01-05 Nerviano Medical Sciences S.R.L. Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
EP4125915B1 (en) 2020-03-23 2024-04-17 Eli Lilly and Company Combination therapy with a mutant idh inhibitor
AU2021241471B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Method for treating IDH1 inhibitor-resistant subjects
IL296141A (en) * 2020-03-23 2022-11-01 Lilly Co Eli Combined treatment with mutant idh inhibitor and bcl-2 inhibitor
US20230174550A1 (en) * 2020-06-28 2023-06-08 Wigen Biomedicine Technology (shanghai) Co., Ltd. Idh mutant inhibitor and use thereof
EP4181927A1 (en) 2020-07-20 2023-05-24 Eli Lilly and Company Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
CN117460514A (zh) 2021-06-09 2024-01-26 伊莱利利公司 用于治疗idh抑制剂耐药的对象的方法
CN117460512A (zh) 2021-06-15 2024-01-26 微境生物医药科技(上海)有限公司 Idh突变体抑制剂及其用途
WO2023018955A1 (en) 2021-08-13 2023-02-16 Eli Lilly And Company Solid forms of 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2- enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h- pyrimido[4,5-d] [1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140069235A (ko) * 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
MX2015012822A (es) * 2013-03-14 2016-05-31 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
US10294206B2 (en) * 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
CA2979669A1 (en) * 2015-04-24 2016-10-27 Halliburton Energy Services, Inc. Methods of fabricating ceramic or intermetallic parts
WO2017019429A1 (en) * 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
WO2017213910A1 (en) * 2016-06-06 2017-12-14 Eli Lilly And Company Mutant idh1 inhibitors
PE20190977A1 (es) * 2016-12-16 2019-07-09 Lilly Co Eli Compuestos de 7-feniletilamino-4h-pirimido [4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e ihd2 mutantes

Also Published As

Publication number Publication date
SA519401897B1 (ar) 2022-07-28
PH12019501328A1 (en) 2020-02-24
NZ754115A (en) 2021-07-30
CR20190252A (es) 2019-08-26
ES2941631T3 (es) 2023-05-24
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
CA3045303A1 (en) 2018-06-21
JOP20190142B1 (ar) 2023-03-28
US20200079791A1 (en) 2020-03-12
WO2018111707A1 (en) 2018-06-21
CN110072867A (zh) 2019-07-30
US11649247B2 (en) 2023-05-16
JOP20190142A1 (ar) 2019-06-13
AU2020260493A1 (en) 2020-11-26
AU2020260493B2 (en) 2021-09-09
BR112019009648A2 (pt) 2019-09-10
ES2835281T3 (es) 2021-06-22
MX2019006830A (es) 2019-08-22
TN2019000158A1 (en) 2020-10-05
DK3555105T3 (da) 2020-11-09
KR20190077539A (ko) 2019-07-03
US11629156B2 (en) 2023-04-18
EP3555105A1 (en) 2019-10-23
MA53881A (fr) 2022-04-27
UA123640C2 (uk) 2021-05-05
EA036112B1 (ru) 2020-09-29
IL267236B (en) 2020-08-31
MA47399A (fr) 2019-10-23
MY197313A (en) 2023-06-13
US20210230185A1 (en) 2021-07-29
KR102276022B1 (ko) 2021-07-13
ECSP19042682A (es) 2019-06-30
CO2019005287A2 (es) 2019-05-31
EP3763717B1 (en) 2023-03-08
DOP2019000163A (es) 2019-07-15
PT3555105T (pt) 2020-12-21
AU2017378060A1 (en) 2019-05-30
EP3763717A1 (en) 2021-01-13
EP3555105B1 (en) 2020-10-28
MA47399B1 (fr) 2021-02-26
LT3555105T (lt) 2021-01-11
EA201991161A1 (ru) 2019-11-29
JP6793836B2 (ja) 2020-12-02
RS61108B1 (sr) 2020-12-31
CA3045303C (en) 2022-05-17
CN115109075A (zh) 2022-09-27
CY1123577T1 (el) 2022-03-24
HRP20201882T1 (hr) 2021-01-22
HUE052067T2 (hu) 2021-04-28
PE20190977A1 (es) 2019-07-09
JP2020502157A (ja) 2020-01-23
CL2019001551A1 (es) 2019-10-25
CN110072867B (zh) 2022-07-08
IL267236A (en) 2019-08-29
MD3555105T2 (ro) 2021-01-31
AU2017378060B2 (en) 2020-09-03
PL3555105T3 (pl) 2021-05-17

Similar Documents

Publication Publication Date Title
SI3555105T1 (sl) Spojine 7-feniletilamino-4H-pirimido(4,5-D)(1,3)oksazin-2-ona kot inhibitorji mutiranih IDH1 in IDH2
EP3880208A4 (en) KRAS G12C INHIBITORS
IL287223B1 (en) kras g12c inhibitors and methods of using them
IL262867B (en) kras g12c inhibitors
IL279363A (en) PCSK9 antagonist compounds
HK1252821A1 (zh) 用於治療具有rtk突變細胞的患者的組合物和方法
ZA201802181B (en) 2¿phenyl¿3,4¿dihydropyrrolo[2,1 ¿f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
EP3091984A4 (en) Substituted benzoxazine and related compounds
EP3230234A4 (en) Nitrification inhibitor compositions and methods for preparing the same
EP3810129A4 (en) PCSK9 -ANTAGONISTIC BICYCLO COMPOUNDS
EP3240768A4 (en) Nitrification inhibitor compositions and methods for preparing the same
EP3468555A4 (en) ANTIMICROBIAL CONNECTIONS AND METHOD FOR USE THEREOF
HK1257555A1 (zh) Tec激酶家族之抑制劑
EP3552017A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
PL3310784T3 (pl) Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
HUE060654T2 (hu) Heterokondelzált piridonvegyületek és azok IDH-gátlóként történõ alkalmazása
EP3568018A4 (en) COMPOUNDS AND METHOD OF USE
EP3191447A4 (en) S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
KR102383690B9 (ko) 벤족사진계 혼합물, 및 이의 용도
EP3364976A4 (en) PIPERAZINYL-NORBENZOMORPHAN COMPOUNDS AND METHOD FOR USE THEREOF
EP3192513A4 (en) 7-fluoro-8-chloro-5 -dibenzo[b,e][1,4]diazepine derivatives and use thereof
TH1501007226A (th) สารประกอบ 6,7-ไดไฮโดรไพราโซโล[1,5-a]ไพราซีน-4(5H)-โอน และการใช้ของ สิ่งนั้นในฐานะเป็นสารยับยั้งแอลโลสเตอริกของ mGluR2 รีเซ็ปเตอร์
AU2016901442A0 (en) Methods and compositions for preventing and/or treating cataracts
AU2014903744A0 (en) Nitrification inhibitors and formulations